Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490945 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00490945 is a Phase 2 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT00490945, a Phase 2 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.
Interventions
- DRUG VEC-162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490945
The ClinicalTrials.gov registry entry for NCT00490945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VEC-162 is the first listed.
NCT00490945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490945 about?
NCT00490945 is a clinical study titled "Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers". The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.
What is the current status of trial NCT00490945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-07. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00490945?
The interventions under investigation include: VEC-162 (DRUG).
Who is sponsoring clinical trial NCT00490945?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.